cefpirome
Trade name: cefrom
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Jan 1, 2006 (NCT00280514)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
Cefpirome is a fourth-generation cephalosporin. Cefpirome is considered highly active against Gram-negative bacteria, including Pseudomonas aeruginosa, and Gram-positive bacteria. It binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Cefpirome is a zwitterion with a net charge of zero at physiological pH that penetrates the outer membrane of Gram negative pathogens more rapidly than ceftazidime.
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
Chemistry & pharmacology
SMILES
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3cccc4c3CCC4)CS[C@H]12)c1csc(N)n1- Mol. weight
- 514.59 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL65794 ↗
- ChEMBLCHEMBL2106076 ↗
Also known as
- 3-((2,3-cyclopenteno-1-pyridinium)methyl)-7-(2-syn-methoximino-2-(2-aminothiazole-4-yl)acetamido)ceph-3-em-4-carboxylate
- 5h-1-pyrindinium, 1-((7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-6,7-dihydro-, hydroxide, inner salt, (6r-(6alpha,7beta(z)))-
- cefpirome
- cefpirome
- cefpirome
- cefpirome
- cefpirome
- cefpirome
- cefpirome sulfate
- cefpirome sulfate
- cefpirome sulfate
- cefpirome sulfate
- cefpirome sulfate
- cefrom
- cefrom
- cefrom
- cefrom
- hr 810
- hr-810
- hr-810 sulfate
- hr-810 sulfate
- metran
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00280514 | Phase 4 | Jan 1, 2006 | University of Vienna |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Vienna | Academic/Hospital | 1 | 1 | 1 | 2006 |